Itasca, IL (PRWEB) February 03, 2014
AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, today announced that its SphygmoCor XCEL system has been approved by Health Canada, allowing AtCor to sell its new system to Canadian customers.
Canada’s population is more than 35 million and hypertension (high blood pressure) affects more than one in five Canadian adults. Data from 2006/07 showed 22.7% of the population over 20 years old had been diagnosed with hypertension. According to the Heart and Stroke Foundation of Canada, heart disease and stroke costs the Canadian economy more than C$20.9 billion every year in physician services, hospital costs, lost wages and decreased productivity.
Duncan Ross, CEO of AtCor Medical, said: “We have been successful selling direct in Canada where SphygmoCor is currently used in a number of leading hospitals. SphygmoCor XCEL approval provides AtCor with an excellent opportunity to offer existing clients new technology and expand our share of the clinical market.
“The Canadian health care system is facing the same challenges as others around the world, particularly meeting the increasing costs of servicing the health demands of an aging population. We believe that tools such as SphygmoCor, which can identify risks early and help patients adopt preventative strategies, will be attractive to health authorities, specialists and clinicians. Our technology complements the Public Health Agency of Canada’s 2013-2016 “Preventing Chronic Disease Strategic Plan”, which guides the Agency’s investments in healthy living and chronic disease prevention.”
About AtCor Medical
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,300 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies, and the company’s technology have been featured in over 700 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at http://www.atcormedical.com.